GlassScriptPhysician profile
Emmanuel Appiadu
NPI 1770913444
$9,635.76
in general payments reported to CMS, 2019-2025
24 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,415 · 2022: $1,973 · 2023: $1,600 · 2024: $2,562 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,136 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.22 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,595.16 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,580.33 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,009.94 | 2021-2025 | Caplyta |
| Alkermes, INC. | $808.91 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $788.70 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $743.39 | 2021-2025 | Ingrezza |
| Abbvie INC. | $601.16 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $581.56 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $451.13 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $427.21 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $248.14 | 2021-2025 | Trintellix |
| Indivior INC. | $145.77 | 2021-2025 | Sublocade |
| Eisai INC. | $128.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.11 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $110.92 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $85.27 | 2021-2022 | |
| Pear Therapeutics (US), INC. | $57.80 | 2021 | |
| Lundbeck LLC | $32.05 | 2022-2023 | Rexulti |
| Janssen Biotech, INC. | $28.70 | 2025 | Invega Sustenna |
| Corium, LLC | $23.57 | 2022-2023 | Azstarys |
| Noven Therapeutics, LLC | $21.69 | 2022 | |
| Tris Pharma INC | $19.24 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $12.69 | 2023 | Quviviq |
| Bausch Health US, LLC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Appiadu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.